New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
09:00 EDTXLRNAcceleron Pharma rises 14%
Acceleron Pharma is up 14%, or $4.74, to $38.60
News For XLRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
10:08 EDTXLRNAcceleron to host educational seminar
Subscribe for More Information
07:26 EDTXLRNAcceleron data positive, says JMP Securities
JMP Securities believes that data presented on Acceleron's sotatercept shows compelling evidence of clinical benefit to dialysis patients. The firm thinks the data supports the drug's efficacy in preventing vascular calcification. It reiterates a $52 price target and Outperform rating on the shares.
October 23, 2014
10:54 EDTXLRNAcceleron, Celgene to present sotatercept prelinical interim clinical data
Acceleron Pharma (XLRN) reported that its collaboration partner, Celgene (CELG), and investigators on the sotatercept program will present sotatercept preclinical and interim clinical data at the American Society of Nephrology Kidney Week 2014. The meeting will be held in Philadelphia on November 11-16. Preliminary data, including safety and effects on hemoglobin, bone density and vascular calcification from the ongoing phase 2a clinical trial of sotatercept will be presented on Thursday, November 13. Additionally, data from preclinical studies will be presented on Friday and Saturday, November 13 and 14.
October 15, 2014
10:57 EDTXLRNAcceleron to host educational webcast
Educational webcast on Beta-thalassemia will be held on October 17 at 12:30 pm. Webcast Link
10:52 EDTXLRNAcceleron management to meet with FBR Capital
Subscribe for More Information
October 14, 2014
07:33 EDTXLRNAcceleron initiates ACE-083 Phase 1 clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use